🔗 Share this article

The first new treatments for gonorrhoea in decades are being hailed as a "significant breakthrough" in the fight against increasingly resistant strains of the bacteria, according to researchers.

An International Health Concern

The sexually transmitted infection are escalating around the world, with figures suggesting more than 82 million instances per year. Notably increased rates are reported in the African continent and countries within the WHO's Western Pacific region, which includes Mongolia and China to New Zealand. In England, cases have reached a all-time high, while infection numbers across Europe in 2023 were triple the level compared to figures for 2014.

“The clearance of fresh medications for gonorrhoea is an important and timely advancement in the face of rising global incidence, increasing antimicrobial resistance and the very limited therapeutic options at this time.”

Health officials are particularly alarmed about the surge in treatment-resistant strains. The WHO has classified it as a "priority pathogen". Recent surveillance found that the effectiveness of standard treatments like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Recent Drugs Secure Approval

Zoliflodacin, marketed under the name Nuzolvence, was authorized by the US Food and Drug Administration in December for use against gonorrhoea. This disease can lead to significant complications, including infertility. Scientists believe that focused deployment of this new drug will help delay the development of resistance.

Another new antibiotic, created by the drugmaker GSK, gained clearance in close succession. This treatment, which is additionally indicated for urinary tract infections, was proven in research to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Approach to Creation

Zoliflodacin stemmed from a innovative non-profit model for medication research. The charitable organization GARDP collaborated with the pharmaceutical company its industry partner to see it through.

“This approval marks a major breakthrough in the treatment of highly resistant gonorrhoea, which up to this point has been evolving faster than medical innovation.”

Research Study Data and Global Access

According to results detailed in a major medical journal, zoliflodacin cured the vast majority of uncomplicated infections. This places it at an similar efficacy with the existing first-line therapy, which uses two antibiotics. The study included nearly 1,000 volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, GARDP has the rights to license and sell the drug in a wide range of developing nations.

Medical professionals on the front lines have voiced optimism. The availability of a single-dose, oral treatment of this kind is hailed as a "game-changer" for public health efforts. This is considered vital to lessen the impact of the infection for patients and to prevent the spread of untreatable gonorrhoea worldwide.